Taking on biodefense threats, antibiotics maker Spero inks $54M in government deals
Cambridge, Massachusetts startup Spero Therapeutics is joining forces with US defense organizations to see if their investigational antibiotic could be useful against biodefense threats.
To help find out, Spero was awarded $15.7 million in funding from the Biomedical Advanced Research and Development Authority, or BARDA, with potential to see an additional $28.5 million over the next 5 years.
As part of an inter-agency collaboration, the US Army is stepping up to test Spero’s antibiotic, SPR994, to see how it works against biodefense threats like anthrax, plague, and melioidosis. Those studies will be conducted by the US Army Medical Research Institute of Infectious Diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.